Core Insights - The article highlights the presentation of real-world research data by Nephron (NEFECON) at the 18th International IgA Nephropathy Symposium (IIgANN 2025) [1] - A significant observational study demonstrated the efficacy and safety of NEFECON in treating IgA nephropathy over a 12-month period, confirming its substantial clinical benefits for long-term treatment [1] Group 1 - NEFECON showcased seven real-world research studies from top hospitals in China [1] - The observational study specifically evaluated the effectiveness and safety of NEFECON in IgA nephropathy treatment [1] - Results indicated significant clinical benefits of NEFECON for long-term treatment of IgA nephropathy [1]